Raj Chovatiya, MD, PhD, on Pediatric Clinical Trials and B-VEC's Milestone Approval in Dermatology

Commentary
Video

The assistant professor dermatology at the Northwestern University Feinberg School of Medicine discussed how Vyjuvek’s approval changed the treatment landscape of DEB.

“Hats off to everybody who focuses on [the pediatric] population, when it comes to studies, it is truly not easy. But for genetic diseases that really affect the youngest of the young and can have really bad long-term outcomes, it's really the only way that we can kind of figure out some of these therapies.”

Krystal Biotech’s marketing authorization application for beremagene geperpavec (B-VEC) is up for review in the European Union, following its United States FDA approval in May 2023 for treating dystrophic epidermolysis bullosa (DEB) under the name Vyjuvek.1,2

B-VEC is unique among gene therapies as it is topically applied in a gel droplet form to the skin and is redosable, with caregivers applying it to wounds on a weekly basis. Rather than using an adeno-associated virus vector, it is a herpes simplex virus type 1-based gene therapy that delivers COL7A1, mutations in which cause DEB, to restore collagen 7 protein, and may have potential to treat other disorders in which COL7A1 is impacted.

CGTLive spoke with Raj Chovatiya, MD, PhD, assistant professor dermatology at the Northwestern University Feinberg School of Medicine, to learn more about the landmark approval of Vyjuvek and what it may mean for the dermatology field. He also discussed some challenges in conducting clinical trials in a pediatric population.

REFERENCES
1. Krystal Biotech announces EMA validation of marketing authorization application for VYJUVEK for the treatment of dystrophic epidermolysis bullosa. News release. Krystal Biotech, Inc. November 27, 2023. Accessed November 27, 2023. https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-ema-validation-marketing-authorization
2. Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa. News release. Krystal Biotech. May 19, 2023. Accessed November 27, 2023. https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-receives-fda-approval-first-ever-redosable-gene
Related Videos
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
© 2024 MJH Life Sciences

All rights reserved.